Have a feature idea you'd love to see implemented?
Let us know!
BBIO BridgeBio Pharma Inc
Price (delayed)
$24.28
Market cap
$4.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.63
Enterprise value
$5.75B
BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in
Highlights
BridgeBio Pharma's gross margin has soared by 85% YoY
BBIO's EPS is up by 30% year-on-year and by 18% since the previous quarter
BBIO's equity is up by 20% year-on-year but it is down by 4.1% since the previous quarter
BridgeBio Pharma's quick ratio has decreased by 18% from the previous quarter but it has increased by 17% YoY
Key stats
What are the main financial stats of BBIO
Market
Valuations
Earnings
Shares outstanding
188.03M
Market cap
$4.57B
Enterprise value
$5.75B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
20.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.23
Revenue
$219.12M
EBIT
-$366.84M
EBITDA
-$356.34M
Free cash flow
-$416.49M
Per share
Balance sheet
Liquidity
EPS
-$2.63
Free cash flow per share
-$2.22
Book value per share
-$5.84
Revenue per share
$1.17
TBVPS
$4.1
Total assets
$794.38M
Total liabilities
$1.88B
Debt
$1.73B
Equity
-$1.09B
Working capital
$481.87M
Debt to equity
-1.58
Current ratio
4.59
Quick ratio
4.37
Net debt/EBITDA
-3.32
Margins
Efficiency
Dividend
EBITDA margin
-162.6%
Gross margin
98.9%
Net margin
-207.1%
Operating margin
-228.6%
Return on assets
-63.8%
Return on equity
N/A
Return on invested capital
-20.3%
Return on capital employed
-55.6%
Return on sales
-167.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BBIO stock price
How has the BridgeBio Pharma stock price performed over time
Intraday
-0.9%
1 week
-0.7%
1 month
-4.63%
1 year
-4.82%
YTD
-39.86%
QTD
-4.63%
Financial performance
How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$219.12M
Gross profit
$216.73M
Operating income
-$500.82M
Net income
-$453.82M
Gross margin
98.9%
Net margin
-207.1%
BBIO's net margin has surged by 98% year-on-year and by 16% since the previous quarter
BBIO's operating margin has soared by 98% YoY but it is down by 6% QoQ
BridgeBio Pharma's gross margin has soared by 85% YoY
BBIO's net income is up by 21% year-on-year and by 16% since the previous quarter
Growth
What is BridgeBio Pharma's growth rate over time
Valuation
What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
20.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.23
BBIO's EPS is up by 30% year-on-year and by 18% since the previous quarter
BBIO's equity is up by 20% year-on-year but it is down by 4.1% since the previous quarter
The stock's price to sales (P/S) is 93% less than its last 4 quarters average of 302.5 and 91% less than its 5-year quarterly average of 240.1
Efficiency
How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 98% year-on-year and by 19% since the previous quarter
The ROA has grown by 31% YoY and by 24% from the previous quarter
The ROIC has grown by 26% YoY and by 20% from the previous quarter
Dividends
What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BBIO.
Financial health
How did BridgeBio Pharma financials performed over time
BBIO's total assets is 58% smaller than its total liabilities
BBIO's total assets has soared by 58% year-on-year but it is down by 6% since the previous quarter
BridgeBio Pharma's quick ratio has decreased by 18% from the previous quarter but it has increased by 17% YoY
BBIO's debt to equity is down by 24% year-on-year but it is up by 4.2% since the previous quarter
BBIO's equity is up by 20% year-on-year but it is down by 4.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.